Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
WO2021030312A1
Methods and compositions for reducing gene or nucleic acid therapy-related immune responses
WO2021011840A1
Compositions and production of nicked closed-ended dna vectors
WO2021011842A1
Synthetic production of single-stranded adeno associated viral dna vectors
WO2020186150A2
Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics
WO2020186207A2
Non-viral dna vectors and uses thereof for expressing fviii therapeutics
WO2020181182A1
Closed-ended dna (cedna) and immune modulating compounds
WO2020181168A1
Non-active lipid nanoparticles with non-viral, capsid free dna
WO2020168222A1
Modulation of rep protein activity in closed-ended dna (cedna) production
WO2020154645A1
Close-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
WO2020097417A1
Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats
AU2019226527A1
Closed-ended DNA (ceDNA) vectors for insertion of transgenes at genomic safe harbors (GSH) in humans and murine genomes
AU2019226526A1
Identifying and characterizing genomic safe harbors (GSH) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified GSH loci
BR112020017060A2
CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED END DNA VECTORS (CEDNA)
CA3091250A1
Non-viral dna vectors and uses thereof for antibody and fusion protein production
CN111868242A
Closed-ended DNA vectors obtainable from cell-free synthesis and method for obtaining a ceDNA vector
WO2019113310A1
Gene editing using a modified closed-ended dna (cedna)
CN111132699A
Modified closed-ended DNA (CEDNA)
CN111295448A
Lipid nanoparticle formulation of non-viral capsid-free DNA vectors
